Capstone Therapeutics Corp.

CAPS Basic Materials Building Materials

Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024. In the quarter to June 2026, revenue grew 67.1%, EPS grew 15.4%, free cash flow grew 73.4% and total debt rose 45.9%, each against the same quarter a year earlier.

0.09 0.01 −10.00%
Market cap
$2.7M
P/E
0.0×
Fwd P/E
5.3×
Dividend yield
—
F-score
3/9
Altman Z
−5.67
Beneish M
−3.81
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(56.01%) (468.45%) (112.23%) (114.39%)
ROA
(21.23%) (44.49%) (40.41%) (41.47%)
ROIC
(3.84%) (19.57%) (18.84%) (17.20%)
Return on Tangible Assets
(789.20%) (1,014.10%) (3,886.93%) (1,286.95%)
Average Days of Receivables
47.10 37.87 48.77 56.80
Free Cash Flow per Share
(0.22) (0.85) (0.54) (0.30)
Free Cash Flow
(1.23) (4.53) (5.07) (3.81)
Capital Expenditures
(0.02) (0.12) (0.13) (0.21)
Other line items
Cash ROIC
(2.62%) (12.41%) (13.51%) (10.00%)
Accounts Receivable Turnover
0.00 12.30 9.04 8.11
Accounts Payable Turnover
11.14 8.74 6.91 8.64
Inventory Turnover
0.00 2.70 2.81 3.46
Average Days of Payables
57.20 50.14 64.82 55.31
Days of Inventory on Hand
127.10 172.56 168.20 133.09
Tax Rate
0.00 0.00 0.03 0.03
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
26.68% 30.66% 31.17% 30.22%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
(1.68) (2.83) (2.47) (1.73)
Operating CF/Net income
0.19 0.20 0.23 0.16
Depreciation/Fixed assets
0.32 1.23 1.50 2.24
Capex/Depreciation
(0.04) (0.05) (0.04) (0.05)
Revenue per Share
7.85 8.81 5.53 4.77
Operating CF per Share
(0.21) (0.83) (0.53) (0.28)
Capex per Share
0.00 (0.02) (0.01) (0.02)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates